The European Patent Office (EPO) has granted patent EP3424955B1 for a method of producing an anti-Trop2 antibody-drug conjugate. This patent, published on March 18, 2026, signifies the formal recognition of novel production techniques for a specific class of therapeutic agents.

While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it is highly relevant for pharmaceutical and biotechnology companies involved in the development and manufacturing of antibody-drug conjugates. Companies operating in this space should be aware of this granted patent as it may impact their freedom to operate or require licensing agreements for the specific production methods described.